Related Experiment Videos
The evolutional stage changes in sarcoidosis on gallium-67 scintigraphy
1Department of Nuclear Medicine, The Brooklyn Hospital Center, New York 11201, USA.
Annals of Nuclear Medicine
|June 24, 1998
Summary
Gallium-67 scintigraphy reveals variable sarcoidosis stage changes during steroid therapy. While unpredictable, it remains crucial for diagnosing and evaluating sarcoidosis, especially with stage IV disease.
Area of Science:
- Nuclear Medicine
- Pulmonary Medicine
- Immunology
Background:
- Gallium-67 scintigraphy is the preferred imaging method for monitoring active sarcoidosis.
- Understanding disease progression during treatment is vital for patient management.
Purpose of the Study:
- To analyze the evolutional stage changes in sarcoidosis patients undergoing steroid therapy using Gallium-67 scintigraphy.
- To assess the predictability of these changes.
Main Methods:
- Eighty-six biopsy-proven sarcoidosis patients were evaluated.
- Thirty-six patients had baseline and follow-up Gallium-67 scintigraphy (136 studies total).
- Initial follow-ups occurred 4-12 months post-baseline.
Main Results:
- 47.2% of patients were in stage IV at baseline.
- Following steroid therapy, 63.9% showed stage changes, with 22.2% achieving complete remission.
- 13 patients remained in the same stage, while others reverted or became active.
Conclusions:
- Evolutional stage changes in sarcoidosis during steroid therapy are variable and unpredictable.
- Gallium-67 scintigraphy is valuable for sarcoidosis diagnosis and prognosis, especially for stage IV disease.
- Despite variability, scintigraphy aids in assessing treatment response and disease activity.